Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -$14.1 million.

  • Northwest Biotherapeutics' Free Cash Flow fell 67.62% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.9 million, marking a year-over-year increase of 7.78%. This contributed to the annual value of -$58.0 million for FY2024, which is 1.68% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Free Cash Flow of -$14.1 million as of Q3 2025, which was down 101.59% from -$7.0 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Free Cash Flow peaked at -$7.0 million during Q2 2025, and registered a low of -$20.3 million during Q4 2024.
  • In the last 3 years, Northwest Biotherapeutics' Free Cash Flow had a median value of -$12.8 million in 2023 and averaged -$13.2 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 83.75% in 2022, then skyrocketed by 58.18% in 2025.
  • Northwest Biotherapeutics' Free Cash Flow (Quarterly) stood at -$12.8 million in 2021, then rose by 13.99% to -$11.0 million in 2022, then crashed by 57.83% to -$17.4 million in 2023, then decreased by 16.59% to -$20.3 million in 2024, then plummeted by 67.62% to -$14.1 million in 2025.
  • Its Free Cash Flow stands at -$14.1 million for Q3 2025, versus -$7.0 million for Q2 2025 and -$9.5 million for Q1 2025.